These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 956392)

  • 1. Hematologic and clinical responses in patients with sickle cell anemia after chronic extracorporeal red cell carbamylation.
    Deiderich DA; Trueworthy RC; Gill P; Cader AM; Larsen WE
    J Clin Invest; 1976 Sep; 58(3):642-53. PubMed ID: 956392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracorporeal treatment with cyanate in sickle cell disease: preliminary observations in four patients.
    Langer EE; Stamatoyannopoulos G; Hlastala MP; Adamson JW; Figley M; Labbe RF; Detter JC; Finch CA
    J Lab Clin Med; 1976 Mar; 87(3):462-74. PubMed ID: 1249477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Life span of carbamylated red cells in sickle cell anemia.
    Milner PF; Charache S
    J Clin Invest; 1973 Dec; 52(12):3161-71. PubMed ID: 4750447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of hemoglobin carbamylation on the survival of human sickle cell erythrocytes in rats.
    Castro O; Orlin J; Finch SC
    Yale J Biol Med; 1974 Mar; 47(1):55-60. PubMed ID: 4825087
    [No Abstract]   [Full Text] [Related]  

  • 5. Carbamylation distributions in extracorporeal treatment of sickle cell anemia.
    Uvelli DA; Agodoa LC; Babb AL
    J Lab Clin Med; 1978 Jun; 91(6):939-47. PubMed ID: 650059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of carbamyl phosphate and sodium cyanate on protein synthesis and glutathione concentration in human sickle cell and rabbit reticulocytes.
    Freedman ML; Forte FJ; Roseman J
    J Pharmacol Exp Ther; 1975 Nov; 195(2):340-6. PubMed ID: 1185603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies of a continuous extracorporeal cyanate treatment system for patients with sickle cell disease.
    Lee MY; Uvelli DA; Agodoa LC; Scribner BH; Finch CA; Babb AL
    J Lab Clin Med; 1982 Sep; 100(3):334-44. PubMed ID: 7108348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary studies of continuous extracorporeal carbamylation in the treatment of sickle cell anemia.
    Balcerzak SP; Grever MR; Sing DE; Bishop JN; Segal ML
    J Lab Clin Med; 1982 Sep; 100(3):345-55. PubMed ID: 7108349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of cyanate in vitro on red blood cell metabolism and function in sickle cell anemia.
    De Furia FG; Miller DR; Cerami A; Manning JM
    J Clin Invest; 1972 Mar; 51(3):566-74. PubMed ID: 5011101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased life span and membrane damage of carbamylated erythrocytes in vitro.
    Lane TA; Burka ER
    Blood; 1976 Jun; 47(6):909-17. PubMed ID: 1276471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of filterability of sickle cells by cyanate: an effect independent of oxygen saturation.
    Wagner SM; Bishop J; Flanigan PW; Bromberg PA; Balcerzak SP
    J Lab Clin Med; 1975 Mar; 85(3):445-50. PubMed ID: 1117207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cyanate and 2,3-diphosphoglycerate on sickling. Relationship to oxygenation.
    Jensen M; Bunn HF; Halikas G; Kan YW; Nathan DG
    J Clin Invest; 1973 Oct; 52(10):2542-7. PubMed ID: 4729047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of the carbamylation kinetics and antisickling mechanism in hemoglobin S blood.
    Uvelli DA; Lee MY; Manning JM; Hlastala MP; Babb AL
    J Lab Clin Med; 1980 May; 95(5):748-58. PubMed ID: 7365317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational changes induced by the addition of carbamyl phosphate to sickle cell hemoglobin.
    Chapman CE; Simons ER
    Biochim Biophys Acta; 1977 Oct; 494(2):408-15. PubMed ID: 911880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous survival of cyanate-treated cryopreserved sickle erythrocytes.
    Castro O; Rana SR; Poillon WN
    Am J Hematol; 1986 Apr; 21(4):409-13. PubMed ID: 3953559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia.
    Bertles JF; Milner PF
    J Clin Invest; 1968 Aug; 47(8):1731-41. PubMed ID: 5666109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Red cell distribution width parallels dense red cell disappearance during painful crises in sickle cell anemia.
    Lawrence C; Fabry ME; Nagel RL
    J Lab Clin Med; 1985 Jun; 105(6):706-10. PubMed ID: 3998622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of the cyanate-hemoglobin reaction in whole blood.
    Uvelli DA; Fry DL; Finch CA; Babb AL
    J Lab Clin Med; 1977 May; 89(5):978-86. PubMed ID: 16070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation.
    Diederich D; Curran M; Odenbaugh A; Diederich A; Core E
    Tex Rep Biol Med; 1980-1981; 40():313-22. PubMed ID: 7323976
    [No Abstract]   [Full Text] [Related]  

  • 20. Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro.
    Cerami A; Manning JM
    Proc Natl Acad Sci U S A; 1971 Jun; 68(6):1180-3. PubMed ID: 5288366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.